How times a day do you take this medicine?
What is Farmabes?
Farmabes is used alone or together with other medicines to treat angina (severe chest pain) or hypertension (high blood pressure). High blood pressure adds to the workload of the heart and arteries. If it continues for a long time, the heart and arteries may not function properly. This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney failure. High blood pressure may also increase the risk of heart attacks. These problems may be less likely to occur if blood pressure is controlled.
Farmabes is a calcium channel blocker. It works by affecting the movement of calcium into the cells of the heart and blood vessels. As a result, Farmabes relaxes the blood vessels and increases the supply of blood and oxygen to the heart while reducing its workload.
Farmabes is available only with your doctor's prescription.
Farmabes is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug.
Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.
Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.
Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.
Farmabes may be used alone or in combination with other antihypertensive medications.
Farmabes is indicated to improve exercise tolerance in patients with chronic stable angina.
DOSAGE AND ADMINISTRATION
Take Farmabes once a day at approximately the same time. Do not chew or crush the tablet.
Initiate dosing at 180 to 240 mg once daily, although some patients may respond to lower doses. Titrate according to blood pressure to a maximum of 540 mg daily. Maximum antihypertensive effect is usually observed by 14 days of chronic therapy.
Initiate dosing at 180 mg once daily and increase dose at intervals of 7 to 14 days if adequate response is not obtained, to a maximum of 360 mg.
Switching To Farmabes Tablets
Patients controlled on Farmabes alone or in combination with other medications may be switched to Farmabes once-a-day at the nearest equivalent total daily dose. Higher doses of Farmabes may be needed in some patients based on clinical response.
How should I use Farmabes?
Use Farmabes 12-hour sustained-release capsules as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Take Farmabes 12-hour sustained-release capsules by mouth with or without food. It is important to take it consistently with regard to meals. If you take it with food, try to always take it with food. If you prefer to take it on an empty stomach, then always try to take it on an empty stomach.
- Swallow Farmabes 12-hour sustained-release capsules whole. Do not break, crush, or chew before swallowing.
- Take Farmabes 12-hour sustained-release capsules on a regular schedule to get the most benefit from it.
- Taking Farmabes 12-hour sustained-release capsules at the same time each day will help you remember to take it.
- Continue to take Farmabes 12-hour sustained-release capsules even if you feel well. Do not miss any doses.
- If you miss a dose of Farmabes 12-hour sustained-release capsules, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Farmabes 12-hour sustained-release capsules.
Uses of Farmabes in details
Farmabes 12-hour sustained-action capsules are used to treat high blood pressure (hypertension). Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. Farmabes is called a calcium channel blocker. It works by relaxing blood vessels in the body and heart so blood can flow more easily. This effect lowers blood pressure. Farmabes may also lower your heart rate.
OTHER USES: This section contains uses of this drug that are not listed in the approved professional labeling for the drug but that may be prescribed by your health care professional. Use this drug for a condition that is listed in this section only if it has been so prescribed by your health care professional.
Farmabes is also used to prevent chest pain (angina). When used regularly, Farmabes can decrease the number and severity of episodes of chest pain from angina. Farmabes may also be used to control your heart rate if you have a fast/irregular heartbeat (such as atrial fibrillation).
How to use Farmabes SR
Take this medication by mouth with or without food, usually twice daily or as directed by your doctor. Swallow the capsules whole. Do not crush or chew the capsules. Doing so can release all of the drug at once and may increase your risk of side effects.
Your doctor may gradually increase your dose. Follow your doctor's instructions carefully. The dosage is based on your medical condition, response to treatment, and other medications you may be taking. Be sure to tell your doctor and pharmacist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).
Use this medication regularly to get the most benefit from it. To help you remember, use it at the same times each day. It is important to continue taking this medication even if you feel well. Most people with high blood pressure do not feel sick.
If this medication is used for angina, this medication must be taken regularly to be effective. It should not be used to treat angina when it occurs. Use other medications (such as nitroglycerin placed under the tongue) to relieve an angina attack as directed by your doctor. Consult your doctor or pharmacist for details.
It may take up to 2 weeks before you get the full benefit of this drug. Tell your doctor if your condition persists or worsens (for example, your routine blood pressure readings remain high or increase).
Farmabes is 1,5-benzothiazepin-4(5H)one,3-(acetyloxy)-5[2-(dimethylamino)-ethyl]-2-3-dihydro-2-(4-methoxyphenyl),-monohydrochloride,(+)-cis-. It has an empirical formula of C22H26N2O4S·HCl and a molecular weight of 450.98.
Farmabes is a white to off-white crystalline powder with a bitter taste. It is soluble in water, methanol and chloroform.
Patients controlled on Farmabes alone or in combination with other medications may be switched to Farmabes (Farmabes Extended-Release Capsules, USP) (Once-a-day dosage) at the nearest equivalent total daily dose. Higher doses of Farmabes (Farmabes Extended-Release Capsules, USP) (Once-a-day dosage) may be needed in some patients. Patients should be closely monitored. Subsequent titration to higher or lower doses may be necessary and should be initiated as clinically warranted. There is limited general clinical experience with doses above 360 mg, but doses to 540 mg have been studied in clinical trials. The incidence of side effects increases as the dose increases with first-degree AV block, dizziness, and sinus bradycardia bearing the strongest relationship to dose.
Dosage needs to be adjusted by titration to individual patient needs. When used as monotherapy, reasonable starting doses are 180 to 240 mg once daily, although some patients may respond to lower doses. Maximum antihypertensive effect is usually observed by 14 days of chronic therapy; therefore, dosage adjustments should be scheduled accordingly. The usual dosage range studied in clinical trials was 240 to 360 mg once daily. Individual patients may respond to higher doses of up to 480 mg once daily.
Dosages for the treatment of angina should be adjusted to each patient's needs, starting with a dose of 120 or 180 mg once daily. Individual patients may respond to higher doses of up to 480 mg once daily. When necessary, titration may be carried out over a 7- to 14-day period.
Concomitant Use With Other Cardiovascular Agents1. Sublingual NTG
May be taken as required to abort acute anginal attacks during Farmabes (Farmabes Extended-Release Capsules, USP) (Once-a-day dosage) therapy.
2. Prophylactic Nitrate Therapy
Farmabes (Farmabes Extended-Release Capsules, USP) (Once-a-day dosage) may be safely coadministered with short- and long-acting nitrates.
Farmabes (Farmabes Extended-Release Capsules, USP) (Once-a-day dosage) has an additive antihypertensive effect when used with other antihypertensive agents. Therefore, the dosage of Farmabes (Farmabes Extended-Release Capsules, USP) (Once-a-day dosage) or the concomitant antihypertensives may need to be adjusted when adding one to the other.
Due to the potential for additive effects, caution and careful titration are warranted in patients receiving Farmabes concomitantly with any agents known to affect cardiac contractility and/or conduction.
Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with Farmabes.
As with all drugs, care should be exercised when treating patients with multiple medications. Farmabes is both a substrate and an inhibitor of the cytochrome P-450 3A4 enzyme system. Other drugs that are specific substrates, inhibitors, or inducers of this enzyme system may have a significant impact on the efficacy and side effect profile of Farmabes. Patients taking other drugs that are substrates of CYP450 3A4, especially patients with renal and/or hepatic impairment, may require dosage adjustment when starting or stopping concomitantly administered Farmabes in order to maintain optimum therapeutic blood levels.
The depression of cardiac contractility, conductivity, and automaticity, as well as the vascular dilation associated with anesthetics, may be potentiated by calcium channel blockers. When used concomitantly, anesthetics and calcium blockers should be titrated carefully.
Studies showed that Farmabes increased the AUC of midazolam and triazolam by 3-to 4-fold and the Cmax by 2-fold, compared to placebo. The elimination half-life of midazolam and triazolam also increased (1.5-to 2.5-fold) during coadministration with Farmabes. These pharmacokinetic effects seen during Farmabes coadministration can result in increased clinical effects (e.g., prolonged sedation) of both midazolam and triazolam.
Controlled and uncontrolled domestic studies suggest that concomitant use of Farmabes and beta-blockers is usually well tolerated. Available data are not sufficient, however, to predict the effects of concomitant treatment, particularly in patients with left ventricular dysfunction or cardiac conduction abnormalities.
Administration of Farmabes (Farmabes) concomitantly with propranolol in five normal volunteers resulted in increased propranolol levels in all subjects, and bioavailability of propranolol was increased approximately 50%. In vitro, propranolol appears to be displaced from its binding sites by Farmabes. If combination therapy is initiated or withdrawn in conjunction with propranolol, an adjustment in the propranolol dose may be warranted.
In nine healthy subjects, Farmabes significantly increased the mean buspirone AUC 5.5-fold and Cmax 4.1-fold compared to placebo. The T½ and Tmax of buspirone were not significantly affected by Farmabes. Enhanced effects and increased toxicity of buspirone may be possible during concomitant administration with Farmabes. Subsequent dose adjustments may be necessary during coadministration, and should be based on clinical assessment.
Concomitant administration of Farmabes with carbamazepine has been reported to result in elevated serum levels of carbamazepine (40% to 72% increase) resulting in toxicity in some cases. Patients receiving these drugs concurrently should be monitored for a potential drug interaction.
A study in six healthy volunteers has shown a significant increase in peak Farmabes plasma levels (58%) and area-under-the-curve (53%) after a 1-week course of cimetidine at 1200 mg per day and a single dose of Farmabes 60 mg. Ranitidine produced smaller, nonsignificant increases. The effect may be mediated by cimetidine's known inhibition of hepatic cytochrome P-450, the enzyme system responsible for the first-pass metabolism of Farmabes. Patients currently receiving Farmabes therapy should be carefully monitored for a change in pharmacological effect when initiating and discontinuing therapy with cimetidine. An adjustment in the Farmabes dose may be warranted.
Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with Farmabes. Monitor heart rate in patients receiving concomitant Farmabes and clonidine.
A pharmacokinetic interaction between Farmabes and cyclosporine has been observed during studies involving renal and cardiac transplant patients. In renal and cardiac transplant recipients, a reduction of cyclosporine trough dose ranging from 15% to 48% was necessary to maintain concentrations similar to those seen prior to the addition of Farmabes. If these agents are to be administered concurrently, cyclosporine concentrations should be monitored, especially when Farmabes therapy is initiated, adjusted, or discontinued. The effect of cyclosporine on Farmabes plasma concentrations has not been evaluated.
Administration of Farmabes with digoxin in 24 healthy male subjects increased plasma digoxin concentrations approximately 20%. Another investigator found no increase in digoxin levels in 12 patients with coronary artery disease. Since there have been conflicting results regarding the effect of digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing Farmabes therapy to avoid possible over-or under-digitalization.
Farmabes significantly increases the AUC (0→infin;) of quinidine by 51%, T½ by 36%, and decreases its CLoral by 33%. Monitoring for quinidine adverse effects may be warranted and the dose adjusted accordingly.
Coadministration of rifampin with Farmabes lowered the Farmabes plasma concentrations to undetectable levels. Coadministration of Farmabes with rifampin or any known CYP3A4 inducer should be avoided when possible, and alternative therapy considered.
Farmabes is an inhibitor of CYP3A4 and has been shown to increase significantly the AUC of some statins. The risk of myopathy and rhabdomyolysis with statins metabolized by CYP3A4 may be increased with concomitant use of Farmabes. When possible, use a non-CYP3A4-metabolized statin together with Farmabes; otherwise, dose adjustments for both Farmabes and the statin should be considered along with close monitoring for signs and symptoms of any statin related adverse events.
In a healthy volunteer cross-over study (N=10), co-administration of a single 20 mg dose of simvastatin at the end of a 14 day regimen with 120 mg BID Farmabes SR resulted in a 5-fold increase in mean simvastatin AUC versus simvastatin alone. Subjects with increased average steady-state exposures of Farmabes showed a greater fold increase in simvastatin exposure. Computer-based simulations showed that at a daily dose of 480 mg of Farmabes, an 8-to 9-fold mean increase in simvastatin AUC can be expected. If co-administration of simvastatin with Farmabes is required, limit the daily doses of simvastatin to 10 mg and Farmabes to 240 mg.
In a ten-subject randomized, open label, 4-way cross-over study, co-administration of Farmabes (120 mg BID Farmabes SR for 2 weeks) with a single 20 mg dose of lovastatin resulted in 3-to 4-fold increase in mean lovastatin AUC and Cmax versus lovastatin alone. In the same study, there was no significant change in 20 mg single dose pravastatin AUC and Cmax during Farmabes coadministration. Farmabes plasma levels were not significantly affected by lovastatin or pravastatin.
Farmabes side effects
Serious adverse reactions have been rare in studies carried out to date, but it should be recognized that patients with impaired ventricular function and cardiac conduction abnormalities have usually been excluded from these studies.
In the hypertension study, the following table presents adverse reactions more common on Farmabes than on placebo (but excluding events with no plausible relationship to treatment), as reported in placebo-controlled hypertension trials in patients receiving a Farmabes extended-release formulation (once-a-day dosing) up to 540 mg.
| Adverse Reactions |
| N=120 |
# pts (%)
| 120-360 mg |
# pts (%)
| 540 mg |
# pts (%)
| Edema lower limb |
| 4 (3) |
| 24 (5) |
| 10 (8) |
In the angina study, the adverse event profile of Farmabes extended-release tablets was consistent with what has been previously described for Farmabes extended-release tablets and other formulations of Farmabes HCl. The most frequent adverse effects experienced by Farmabes extended-release tablets-treated patients were edema lower-limb (6.8%), dizziness (6.4%), fatigue (4.8%), bradycardia (3.6%), first-degree atrioventricular block (3.2%), and cough (2%).
In clinical trials of other Farmabes formulations involving over 3200 patients, the most common events (i.e. greater than 1%) were edema (4.6%), headache (4.6%), dizziness (3.5%), asthenia (2.6%), first-degree AV block (2.4%), bradycardia (1.7%), flushing (1.4%), nausea (1.4%), and rash (1.2%).
In addition, the following events were reported infrequently (less than 1%) in angina or hypertension trials:
Cardiovascular: Angina, arrhythmia, AV block (second- or third-degree), bundle branch block, congestive heart failure, ECG abnormalities, hypotension, palpitations, syncope, tachycardia, ventricular extrasystoles.
Nervous System: Abnormal dreams, amnesia, depression, gait abnormality, hallucinations, insomnia, nervousness, paresthesia, personality change, somnolence, tinnitus, tremor.
Gastrointestinal: Anorexia, constipation, diarrhea, dry mouth, dysgeusia, dyspepsia, mild elevations of SGOT, SGPT, LDH, and alkaline phosphatase, thirst, vomiting, weight increase.
Dermatological: Petechiae, photosensitivity, pruritus, urticaria.
Other: Amblyopia, CPK increase, dyspnea, epistaxis, eye irritation, hyperglycemia, hyperuricemia, impotence, muscle cramps, nasal congestion, nocturia, osteoarticular pain, polyuria, sexual difficulties.
The following postmarketing events have been reported infrequently in patients receiving Farmabes: acute generalized exanthematous pustulosis, allergic reactions, alopecia, angioedema (including facial or periorbital edema), asystole, erythema multiforme (including Stevens-Johnson syndrome, toxic epidermal necrolysis), exfoliative dermatitis, extrapyramidal symptoms, gingival hyperplasia, hemolytic anemia, increased bleeding time, leukopenia, photosensitivity (including lichenoid keratosis and hyperpigmentation at sun-exposed skin areas), purpura, retinopathy, myopathy, and thrombocytopenia. In addition, events such as myocardial infarction have been observed which are not readily distinguishable from the natural history of the disease in these patients. A number of well-documented cases of generalized rash, some characterized as leukocytoclastic vasculitis, have been reported. However, a definitive cause and effect relationship between these events and Farmabes therapy is yet to be established.
To report SUSPECTED ADVERSE REACTIONS, contact Actavis at 1-800-272-5525 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Do not use this medication if you have certain heart conditions such as "sick sinus syndrome" or "AV block" (unless you have a pacemaker), low blood pressure, or if you have recently had a heart attack.
Before taking Farmabes, tell your doctor if you have kidney disease, liver disease, or congestive heart failure.
Farmabes may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert.
Do not stop taking this medication without first talking to your doctor. If you stop taking Farmabes suddenly, your condition may become worse.
Farmabes may be only part of a complete program of treatment that also includes diet, exercise, and other medications. Follow your diet, medication, and exercise routines very closely.
If you are being treated for high blood pressure, keep using this medication even if you feel well. High blood pressure often has no symptoms.
Active ingredient matches for Farmabes:
Diltiazem in Indonesia.
Diltiazem HCl in Indonesia.
Diltiazem hydrochloride in Indonesia.
|Unit description / dosage (Manufacturer)||Price, USD|
|Farmabes 30 mg x 100's||$ 5.58|
|Farmabes / vial 5 mg/1 mL x 5 mL x 1's||$ 11.16|
List of Farmabes substitutes (brand and generic names):
|Fada Diltiazem (Argentina)|
|Tablet; Oral; Diltiazem Hydrochloride 30 mg|
|Tablet; Oral; Diltiazem Hydrochloride 60 mg|
|Capsule, Sustained Release; Oral; Diltiazem Hydrochloride 120 mg|
|Capsule, Sustained Release; Oral; Diltiazem Hydrochloride 60 mg|
|Capsule, Sustained Release; Oral; Diltiazem Hydrochloride 90 mg|
|GenRX Diltiazem (Australia)|
|Tablet; Oral; Diltiazem Hydrochloride 60 mg|
|GenRx Diltiazem CD|
|Capsule; Oral; Diltiazem Hydrochloride 180 mg|
|Capsule; Oral; Diltiazem Hydrochloride 240 mg|
|Tablet; Oral; Diltiazem Hydrochloride 30 mg (Laboratorios chile)|
|Tablet; Oral; Diltiazem Hydrochloride 60 mg (Laboratorios chile)|
|Hart A.P. (Paraguay)|
|Hart CD (Argentina)|
|HEARTIL Modified Release Capsule/ Tablet / 90mg / 10 units (Life Medicare)||$ 0.76|
|HEARTIL Modified Release Capsule/ Tablet / 120mg / 10 units (Life Medicare)||$ 0.87|
|90 mg x 10's (Life Medicare)||$ 0.84|
|120 mg x 10's (Life Medicare)||$ 0.87|
|Heartil 90mg TAB / 10 (Life Medicare)||$ 0.84|
|Heartil 120mg TAB / 10 (Life Medicare)||$ 0.87|
|HEARTIL 90MG TABLET 1 strip / 10 tablets each (Life Medicare)||$ 0.85|
|HEARTIL modified-release tab 90 mg x 10's (Life Medicare)||$ 0.84|
|HEARTIL modified-release tab 120 mg x 10's (Life Medicare)||$ 0.87|
|Heartil 90mg TAB / 10 (Life Medicare)||$ 0.84|
|Heartil 120mg TAB / 10 (Life Medicare)||$ 0.87|
|Heartil 90mg Tablet (Life Medicare)||$ 0.09|
|Heartil CR 120 mg Tablet (Life Medicare & Biotech Pvt. Ltd.)||$ 0.09|
|Heartil CR 90 mg Tablet (Life Medicare & Biotech Pvt. Ltd.)||$ 0.08|
|Herben (South Korea)|
|Herben Retard (South Korea)|
|Herben SR (South Korea)|
|Herbesser (Bangladesh, China, Hong Kong, Indonesia, Japan, Malaysia, Myanmar, Portugal, Singapore, Taiwan, Thailand)|
|90 mg x 100's (Tanabe)|
|100 mg x 100's (Tanabe)|
|200 mg x 100's (Tanabe)|
|Herbesser 30 30 mg x 1, 000's (Tanabe)||$ 1620.00|
|Herbesser 60 60 mg x 1, 000's (Tanabe)||$ 3000.00|
|Herbesser 30 30 mg x 100's (Tanabe)|
|Herbesser 30 30 mg x 1, 000's (Tanabe)|
- PubChem. "diltiazem". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "diltiazem". http://www.drugbank.ca/drugs/DB00343 (accessed September 17, 2018).
- MeSH. "Cardiovascular Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
ReviewsThe results of a survey conducted on ndrugs.com for Farmabes are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Farmabes. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
Consumer reported usefulNo survey data has been collected yet
Consumer reported price estimatesNo survey data has been collected yet
Consumer reported time for resultsNo survey data has been collected yet
Consumer reported ageNo survey data has been collected yet
There are no reviews yet. Be the first to write one!
Information checked by Dr. Sachin Kumar, MD Pharmacology